The first coronavirus vaccine is now considered “safe for humans” in a breakthrough study.
Researchers from the Beijing Institute of Biotechnology in Beijing, China, who conducted the study, say the vaccine triggers a rapid immune response to the deadly disease.
The trial was conducted in 109 healthy adults between 18 and 60 years of age and showed promising results after 28 days, with final results to be evaluated within six months.
New research published in The Lancet medical journal considers the finding to be “an important milestone.”
“The trial shows that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells within 14 days, making it a potential candidate for further research,” said Professor Wei Chen of said the Beijing Institute of Biotechnology.
“These results are an important milestone.
“The challenges in developing a COVD-19 vaccine are unprecedented and the ability to trigger these immune responses does not necessarily mean that the vaccine will protect people from COVID-19.
“This result shows a promising vision for the development of COVID-19 vaccines, but we are far from ready for everyone.”
Further studies are needed to determine whether the immune response it causes can effectively protect against SARS-CoV-2 infection, but the signs are promising.
The creation of an effective vaccine to defeat the deadly virus is considered the long-term solution for controlling the COVID-19 pandemic.
Currently, more than 100 candidate COVID-19 vaccines are under development worldwide.
The new ‘Ad5-vectored COVID-19 vaccine’ is the first to be tested in humans.
It uses an attenuated cold virus to deliver genetic material that makes the coronavirus into human cells.